Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 5/2015

01-05-2015 | Acknowledgement to Referees

Acknowledgement to referees

Published in: Acta Neuropathologica | Issue 5/2015

Login to get access

Excerpt

The Editorial Board of Acta Neuropathologica is grateful to the following referees for their invaluable advise and support (Jan 01, 2014–Dec 31, 2014). …
Metadata
Title
Acknowledgement to referees
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
Acta Neuropathologica / Issue 5/2015
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-015-1414-3

Other articles of this Issue 5/2015

Acta Neuropathologica 5/2015 Go to the issue

Position Paper

PART is part of Alzheimer disease

Original Paper

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

Review

Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken

Original Paper

Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers

Correspondence

PART, a distinct tauopathy, different from classical sporadic Alzheimer disease

Original Paper

M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator